Nuveen
ARQT icon

Nuveen’s Arcutis Biotherapeutics ARQT Stock Holding History

Nuveen’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9M Sell
834,261
-67,873
-8% -$1.58M 0.01% 1209
2026
Q1 		$21.3M Sell
902,134
-480,026
-35% -$12.3M 0.01% 1099
2025
Q4 		$40.1M Buy
1,382,160
+11,804
+0.9% +$302K 0.01% 757
2025
Q3 		$25.8M Buy
1,370,356
+604,777
+79% +$9.54M 0.01% 985
2025
Q2 		$10.7M Sell
765,579
-50,237
-6% -$704K ﹤0.01% 1466
2025
Q1 		$12.8M Buy
815,816
+448,930
+122% +$6.32M ﹤0.01% 1406
2024
Q4 		$5.11M Sell
366,886
-440,764
-55% -$4.83M ﹤0.01% 1973
2024
Q3 		$7.51M Buy
807,650
+72,608
+10% +$717K ﹤0.01% 1780
2024
Q2 		$6.84M Buy
735,042
+486,856
+196% +$4.4M ﹤0.01% 1787
2024
Q1 		$2.46M Buy
248,186
+34,351
+16% +$256K ﹤0.01% 2303
2023
Q4 		$691K Sell
213,835
-5,342
-2% -$14.5K ﹤0.01% 2893
2023
Q3 		$1.16M Buy
219,177
+6,481
+3% +$55.1K ﹤0.01% 2518
2023
Q2 		$2.03M Buy
212,696
+108,935
+105% +$1.21M ﹤0.01% 2343
2023
Q1 		$1.14M Sell
103,761
-1,025
-1% -$14.8K ﹤0.01% 2562
2022
Q4 		$1.55M Sell
104,786
-428,089
-80% -$7.48M ﹤0.01% 2492
2022
Q3 		$10.2M Buy
532,875
+171,732
+48% +$3.89M ﹤0.01% 1463
2022
Q2 		$7.7M Buy
361,143
+144,763
+67% +$2.97M ﹤0.01% 1682
2022
Q1 		$3.57M Buy
216,380
+5,641
+3% +$95.4K ﹤0.01% 2243
2021
Q4 		$4.37M Sell
210,739
-8,653
-4% -$172K ﹤0.01% 2198
2021
Q3 		$4.97M Sell
219,392
-44,454
-17% -$1.01M ﹤0.01% 2210
2021
Q2 		$7.2M Buy
263,846
+40,838
+18% +$1.15M ﹤0.01% 2060
2021
Q1 		$6.45M Buy
223,008
+42,366
+23% +$1.32M ﹤0.01% 2041
2020
Q4 		$5.08M Buy
180,642
+112,262
+164% +$2.75M ﹤0.01% 2068
2020
Q3 		$2M Buy
68,380
+24,425
+56% +$653K ﹤0.01% 2388
2020
Q2 		$1.33M Buy
43,955
+5,059
+13% +$146K ﹤0.01% 2500
2020
Q1 		$1.16M Buy
+38,896
New +$1.05M ﹤0.01% 2449

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nuveen's ARQT Position: Q2 2026 in Review

Nuveen reduced its Arcutis Biotherapeutics (ARQT) stake by 7.5% in Q2 2026, selling an estimated $1.58M and leaving 834,261 shares worth $21.9M. The position accounts for 0.01% of the portfolio, ranked #1209.

Nuveen first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $40.1M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Nuveen held 834,261 shares of Arcutis Biotherapeutics worth $21.9M as of Q2 2026.
  • Nuveen sold 67,873 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.58M.
  • Arcutis Biotherapeutics made up 0.01% of Nuveen's portfolio in Q2 2026, its #1209 holding.
  • Nuveen first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Nuveen's Arcutis Biotherapeutics position peaked at $40.1M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.